|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-2-21
|
|
pubmed:abstractText |
MicroRNA-221 (miR-221) is known to be abnormally expressed in malignant melanoma (MM) cells, and it favors the induction of the malignant phenotype through down-modulation of p27Kip1/CDKN1B and the c-KIT receptor. This suggests that the serum level of miR-221 might increase in patients with MM and thus could be used as a new tumor marker.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1873-569X
|
|
pubmed:author |
pubmed-author:FukushimaSatoshiS,
pubmed-author:HondaNoritoshiN,
pubmed-author:IhnHironobuH,
pubmed-author:InoueYujiY,
pubmed-author:IshiharaTsuyoshiT,
pubmed-author:JinninMasatoshiM,
pubmed-author:KakimotoAsakoA,
pubmed-author:KanemaruHisashiH,
pubmed-author:MasuguchiShinichiS,
pubmed-author:OyamaRieR,
pubmed-author:YamashitaJunjiJ
|
|
pubmed:copyrightInfo |
Copyright © 2011 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
187-93
|
|
pubmed:meshHeading |
pubmed-meshheading:21273047-Adult,
pubmed-meshheading:21273047-Aged,
pubmed-meshheading:21273047-Aged, 80 and over,
pubmed-meshheading:21273047-Case-Control Studies,
pubmed-meshheading:21273047-Disease Progression,
pubmed-meshheading:21273047-Female,
pubmed-meshheading:21273047-Follow-Up Studies,
pubmed-meshheading:21273047-Humans,
pubmed-meshheading:21273047-Male,
pubmed-meshheading:21273047-Melanoma,
pubmed-meshheading:21273047-MicroRNAs,
pubmed-meshheading:21273047-Middle Aged,
pubmed-meshheading:21273047-Neoplasm Staging,
pubmed-meshheading:21273047-Prognosis,
pubmed-meshheading:21273047-Skin Neoplasms,
pubmed-meshheading:21273047-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.
|
|
pubmed:affiliation |
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
